Plain-English translation of NCT06786533 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new treatment called HG-CT-1, which uses your own immune cells that have been specially redesigned in a lab to fight acute myeloid leukemia (AML) — a serious blood cancer. The treatment targets cancer cells that have specific proteins on their surface. Researchers want to find the safest and most effective dose of this medication before making it available more broadly.
Many patients with AML find that standard chemotherapy no longer works, or their cancer comes back after treatment. This trial exists because there's an urgent need for new options for these patients, and the medication being tested offers a completely different approach by harnessing the body's own immune system to fight the cancer.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of the specially modified immune cells (HG-CT-1) at the study clinic. The trial starts with small doses and gradually increases the dose in later groups to ensure safety. After receiving the medication, you'll have frequent follow-up visits with blood tests and scans to monitor how well the treatment is working and to watch for any side effects. The study will track your health and cancer response for an extended period to understand both the benefits and risks of this new treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States